Pathogenetic role of 1α,25-dihydroxyvitamin D in sarcoidosis and absorptive hypercalciuria: Different response to prednisolone therapy

J. E. Zerwekh, C. Y C Pak, R. A. Kaplan, J. L. McGuire, K. Upchurch, N. Breslau, R. Johnson

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Intestinal hyperabsorption of calcium (Ca) is frequently observed in sarcoidosis and is characteristic of absorptive hypercalciuria (AH). The potential pathogenetic role of 1α,25-dihydroxyvitamin D [1,25(OH)2D] in these two conditions was sought by a careful assessment of the circulating concentration of this vitamin D metabolite and various measures of Ca metabolism before and after prednisolone therapy. In eight patients with sarcoidosis, prednisolone treatment (50 mg/day for 8 days) produced a significant fall in serum 1,25(OH)2D [4.8 ± 1.9 to 3.3 ± 1.0 (SD) ng/dl; P<0.025], concomitant with a significant decrease in the fractional intestinal Ca absorption (α) from 0.58 ± 0.14 to 0.46 ± 0.13 (±SD; P<0.005). Urinary Ca and serum parathyroid hormone did not change significantly. However, in six patients with AH, prednisolone therapy resulted in a nonsignificant rise in serum 1,25(OH)2D from 3.6 ± 0.7 to 4.4 ± 1.0 ng/dl and no significant fall in α (from 0.73 ± 0.08 to 0.70 ± 0.10). Urinary Ca was significantly increased in AH patients from 230 ± 35 to 343 ± 74 (SD) mg/day (P<0.005), while serum parathyroid hormone rose slightly. Serum 1,25(OH)2D and α were significantly correlated (r=0.543; P<0.05) for patients with sarcoidosis but not in AH patients. These results suggest that the hyperabsorption of calcium in sarcoidosis is dependent on the serum concentration of 1,25(OH)2D, while in AH it may result from additional vitamin D-independent processes.

Original languageEnglish (US)
Pages (from-to)381-386
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume51
Issue number2
StatePublished - 1980

Fingerprint

Hypercalciuria
Sarcoidosis
Prednisolone
Calcium
Serum
Parathyroid Hormone
Vitamin D
Therapeutics
Intestinal Absorption
Metabolites
Metabolism
1,25-dihydroxyvitamin D

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Pathogenetic role of 1α,25-dihydroxyvitamin D in sarcoidosis and absorptive hypercalciuria : Different response to prednisolone therapy. / Zerwekh, J. E.; Pak, C. Y C; Kaplan, R. A.; McGuire, J. L.; Upchurch, K.; Breslau, N.; Johnson, R.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 51, No. 2, 1980, p. 381-386.

Research output: Contribution to journalArticle

Zerwekh, J. E. ; Pak, C. Y C ; Kaplan, R. A. ; McGuire, J. L. ; Upchurch, K. ; Breslau, N. ; Johnson, R. / Pathogenetic role of 1α,25-dihydroxyvitamin D in sarcoidosis and absorptive hypercalciuria : Different response to prednisolone therapy. In: Journal of Clinical Endocrinology and Metabolism. 1980 ; Vol. 51, No. 2. pp. 381-386.
@article{bd40efc0a2de4763ac4af2e4a8417435,
title = "Pathogenetic role of 1α,25-dihydroxyvitamin D in sarcoidosis and absorptive hypercalciuria: Different response to prednisolone therapy",
abstract = "Intestinal hyperabsorption of calcium (Ca) is frequently observed in sarcoidosis and is characteristic of absorptive hypercalciuria (AH). The potential pathogenetic role of 1α,25-dihydroxyvitamin D [1,25(OH)2D] in these two conditions was sought by a careful assessment of the circulating concentration of this vitamin D metabolite and various measures of Ca metabolism before and after prednisolone therapy. In eight patients with sarcoidosis, prednisolone treatment (50 mg/day for 8 days) produced a significant fall in serum 1,25(OH)2D [4.8 ± 1.9 to 3.3 ± 1.0 (SD) ng/dl; P<0.025], concomitant with a significant decrease in the fractional intestinal Ca absorption (α) from 0.58 ± 0.14 to 0.46 ± 0.13 (±SD; P<0.005). Urinary Ca and serum parathyroid hormone did not change significantly. However, in six patients with AH, prednisolone therapy resulted in a nonsignificant rise in serum 1,25(OH)2D from 3.6 ± 0.7 to 4.4 ± 1.0 ng/dl and no significant fall in α (from 0.73 ± 0.08 to 0.70 ± 0.10). Urinary Ca was significantly increased in AH patients from 230 ± 35 to 343 ± 74 (SD) mg/day (P<0.005), while serum parathyroid hormone rose slightly. Serum 1,25(OH)2D and α were significantly correlated (r=0.543; P<0.05) for patients with sarcoidosis but not in AH patients. These results suggest that the hyperabsorption of calcium in sarcoidosis is dependent on the serum concentration of 1,25(OH)2D, while in AH it may result from additional vitamin D-independent processes.",
author = "Zerwekh, {J. E.} and Pak, {C. Y C} and Kaplan, {R. A.} and McGuire, {J. L.} and K. Upchurch and N. Breslau and R. Johnson",
year = "1980",
language = "English (US)",
volume = "51",
pages = "381--386",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Pathogenetic role of 1α,25-dihydroxyvitamin D in sarcoidosis and absorptive hypercalciuria

T2 - Different response to prednisolone therapy

AU - Zerwekh, J. E.

AU - Pak, C. Y C

AU - Kaplan, R. A.

AU - McGuire, J. L.

AU - Upchurch, K.

AU - Breslau, N.

AU - Johnson, R.

PY - 1980

Y1 - 1980

N2 - Intestinal hyperabsorption of calcium (Ca) is frequently observed in sarcoidosis and is characteristic of absorptive hypercalciuria (AH). The potential pathogenetic role of 1α,25-dihydroxyvitamin D [1,25(OH)2D] in these two conditions was sought by a careful assessment of the circulating concentration of this vitamin D metabolite and various measures of Ca metabolism before and after prednisolone therapy. In eight patients with sarcoidosis, prednisolone treatment (50 mg/day for 8 days) produced a significant fall in serum 1,25(OH)2D [4.8 ± 1.9 to 3.3 ± 1.0 (SD) ng/dl; P<0.025], concomitant with a significant decrease in the fractional intestinal Ca absorption (α) from 0.58 ± 0.14 to 0.46 ± 0.13 (±SD; P<0.005). Urinary Ca and serum parathyroid hormone did not change significantly. However, in six patients with AH, prednisolone therapy resulted in a nonsignificant rise in serum 1,25(OH)2D from 3.6 ± 0.7 to 4.4 ± 1.0 ng/dl and no significant fall in α (from 0.73 ± 0.08 to 0.70 ± 0.10). Urinary Ca was significantly increased in AH patients from 230 ± 35 to 343 ± 74 (SD) mg/day (P<0.005), while serum parathyroid hormone rose slightly. Serum 1,25(OH)2D and α were significantly correlated (r=0.543; P<0.05) for patients with sarcoidosis but not in AH patients. These results suggest that the hyperabsorption of calcium in sarcoidosis is dependent on the serum concentration of 1,25(OH)2D, while in AH it may result from additional vitamin D-independent processes.

AB - Intestinal hyperabsorption of calcium (Ca) is frequently observed in sarcoidosis and is characteristic of absorptive hypercalciuria (AH). The potential pathogenetic role of 1α,25-dihydroxyvitamin D [1,25(OH)2D] in these two conditions was sought by a careful assessment of the circulating concentration of this vitamin D metabolite and various measures of Ca metabolism before and after prednisolone therapy. In eight patients with sarcoidosis, prednisolone treatment (50 mg/day for 8 days) produced a significant fall in serum 1,25(OH)2D [4.8 ± 1.9 to 3.3 ± 1.0 (SD) ng/dl; P<0.025], concomitant with a significant decrease in the fractional intestinal Ca absorption (α) from 0.58 ± 0.14 to 0.46 ± 0.13 (±SD; P<0.005). Urinary Ca and serum parathyroid hormone did not change significantly. However, in six patients with AH, prednisolone therapy resulted in a nonsignificant rise in serum 1,25(OH)2D from 3.6 ± 0.7 to 4.4 ± 1.0 ng/dl and no significant fall in α (from 0.73 ± 0.08 to 0.70 ± 0.10). Urinary Ca was significantly increased in AH patients from 230 ± 35 to 343 ± 74 (SD) mg/day (P<0.005), while serum parathyroid hormone rose slightly. Serum 1,25(OH)2D and α were significantly correlated (r=0.543; P<0.05) for patients with sarcoidosis but not in AH patients. These results suggest that the hyperabsorption of calcium in sarcoidosis is dependent on the serum concentration of 1,25(OH)2D, while in AH it may result from additional vitamin D-independent processes.

UR - http://www.scopus.com/inward/record.url?scp=0018965165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018965165&partnerID=8YFLogxK

M3 - Article

C2 - 6893205

AN - SCOPUS:0018965165

VL - 51

SP - 381

EP - 386

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -